British Journal of Medical & Surgical Urology
Volume 1, Issue 3 , Pages 98-106 , November 2008

Tissue characterisation in prostate cancer using a novel ultrasound approach

Received 12 August 2008 ,Revised 24 September 2008 ,Accepted 29 September 2008.

References 

  1. Raja J, Ramachandran N, Munneke G, Patel U. Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Clin Radiol. 2006;61:142–153
  2. Oehr P, Bouchelouche K. Imaging of prostate cancer. Curr Opin Oncol. 2007;19:259–264
  3. Kirkham APS, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate?. Eur Urol. 2006;December (50):1163–1175
  4. Hom JJ, Coakley FV, Simko JP, Qayyum A, Lu Y, et al. Prostate cancer: endorectal MR imaging and MR spectroscopic imaging–distinction of true-positive results from chance-detected lesions. Radiology. 2006;238:192–199
  5. Charlesworth PJ, Harris AL. Mechanisms of disease: angiogenesis in urologic malignancies. Nat Clin Pract Urol. 2006;3:157–169
  6. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumour angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401–409
  7. Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer. 1998;78:940–944
  8. Jager GJ, Ruijter ET, Van de Kaa CA, de la Rosette JJ, Oosterhof GO, Thornbury JR, et al. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology. 1997;203:645–652
  9. Fütterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241:449–458
  10. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol. 2006;176:2432–2437
  11. Wefer AE, Hricak H, Vigneron DB, Coakley FV, Lu Y, Wefer J, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol. 2000;164:400–404
  12. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging: clinicopathologic study. Radiology. 1999;213:473–480
  13. Hasumi M, Suzuki K, Taketomi A, Matsui H, Yamamoto T, et al. The combination of multivoxel MR spectroscopy with MR imaging improve the diagnostic accuracy for localization of prostate cancer. Anticancer Res. 2003;23:4223–4227
  14. Squillaci E, Manenti G, Mancino S, Carlani M, Di Roma M, Colangelo V, et al. MR spectroscopy of prostate cancer. Initial clinical experience. J Exp Clin Cancer Res. 2005;24:523–530
  15. Vilanova JC, Barcelo J. Prostate cancer detection: MR spectroscopic imaging. Abdom Imaging. 2007;32:253–261
  16. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology. 1999;213:481–488
  17. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology. 2006;238:597–603
  18. Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am. 2000;38:115–138
  19. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234:804–814
  20. desouza NM, Reinsberg SA, Scurr ED, Brewster JM, Payne GS . .Magnetic resonance imaging in prostate cancer: value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol. 2007;80:90–95
  21. Desouza NM, Riches SF, Vanas NJ, Morgan VA, Ashley SA, Fisher C, et al. Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol. 2008;63:774–782
  22. Chen AP, Cunningham CH, Ozturk-Isik E, Xu D, Hurd RE, Kelley DA, et al. High-speed 3T MR spectroscopic imaging of prostate with flyback echo-planar encoding. J Magn Reson Imaging. 2007;25:1288–1292
  23. Feinstein SB. The powerful microbubble: from bench to bedside, from intravascular indicator to therapeutic delivery system, and beyond. Am J Physiol Heart Circ Physiol. 2004;H450–H457
  24. Forsberg F, Merton DA, Liu JB, Needleman L, Goldberg BB . Clinical applications of ultrasound contrast agents. Ultrasonics. 1998;36:695–701
  25. Mitterberger M, Pinggera G, Horninger W, Bartsch G, Strasser H, Schaefer G, et al. Comparison of contrast-enhanced colour Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score. J Urol. 2007;178:464–468
  26. Mitterberger M, Pinggera G, Horninger W, Strasser H, Halpern E, Pallwein L, et al. Dutasteride prior to contrast-enhanced colour Doppler ultrasound prostate biopsy increases prostate cancer detection. Eur Urol. 2008;53:112–117
  27. Ophir J, Cespedes I, Ponnekanti H, Yazdi Y, Li X. Elastography: a quantitative method for imaging the elasticity of biological tissues. Ultrason Imag. 1991;13:111–134
  28. Pesavento A, Perrey C, Krueger M, Ermert H. A time efficient and accurate strain estimation concept for ultrasonic elastography using interactive phase zero estimation. IEEE Trans Ultrason Ferroelectr Freq Control. 1999;46:1057–1067
  29. Pallwein L, Mitterberger M, Struve P, Horninger W, Aigner F, Bartsch G. Comparison of sonoelastography guided biopsy with systematic biopsy: impact on prostate cancer detection. Eur Radiol. 2007;17:2278–2285
  30. Nelson ED, Slotoroff CB, Gomella LG, Halpern EJ. Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score. Urology. 2007;70:1136–1140
  31. Salomon G, Köllerman J, Thederan I, Chun FK, Budäus L, Schlomm T, et al. Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. Eur Urol. 2008;[EPub ahead of print]
  32. Pallwein L, Aigner F, Faschingbauer R, Pallwein E, Pinggera G, Bartsch G, et al. Prostate cancer diagnosis: value of real-time elastography. Abdom Imaging. 2008;[EPub ahead of print]
  33. Pallwein L, Mitterberger M, Pinggera G, Aigner F, Pedross F, Gradl J. Sonoelastography of the prostate: comparison with systematic biopsy findings in 492 patients. Eur J Radiol. 2008;65:304–310
  34. Braeckman J, Autier P, Garbar C, Marichal MP, Soviany C, Nir R, et al. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int. 2008;101:293–298
  35. Braeckman J, Autier P, Soviany C, Nir R, Nir D, Michielsen D, et al. The accuracy of transrectal ultrasound supplemented with Prostate HistoScanning™ for detection of small prostate cancers. BJU Int. 2008 [Epub ahead of print].
  36. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology. 2002;60:264–269
  37. Harnden P, Shelley MD, Naylor B, Coles B, Mason MD. Does the extent of carcinoma in prostatic biopsies predict prostate-specific antigen recurrence? A systematic review. Eur Urol. 2008;[Epub ahead of print]
  38. National Institute of Clinical Excellence (UK). NICE prostate cancer management guidelines. www.nice.org.uk.
  39. True LD. Surgical pathology examination of the prostate gland: practice survey by the American Society of Clinical Pathologists. Am J Clin Pathol. 1994;102:572–579
  40. Bossuyt PM, Irwig L, Craig J, Glasziou P. Comparative accuracy: assessing new tests against existing diagnostic pathways. BMJ. 2006;332:1089–1092
  41. Kumar R, Nayyar R, Kumar V, Gupta NP, Hemal AK, Jagannathan NR, et al. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10ng/mL: a follow-up study. Urology. 2008;[Epub ahead of print]
  42. Presti JC. Prostate biopsy: how many cores are enough?. Urol Oncol. 2003;21:135–140
  43. Merrick GS, Gutman S, Andreini H, Taubenslag W, Lindert DL, Curtis R, et al. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol. 2007;52:715–723
  44. Van As NJ, Parker CC. Active surveillance with selective radical treatment for localized prostate cancer. Cancer J. 2007;13:289–294
  45. Eggener E, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007;178:2260–2267
  46. Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer?. Nat Clin Pract Oncol. 2007 November;4:632–642
  47. Singh AK, Kruecker J, Xu S, Glossop N, Guion P, Ullman K, et al. Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int. 2008;101:841–845

PII: S1875-9742(08)00096-7

doi: 10.1016/j.bjmsu.2008.09.003

British Journal of Medical & Surgical Urology
Volume 1, Issue 3 , Pages 98-106 , November 2008

Article Tools

* Image Usage & Resolution